Quantum BioPharma Advances Multiple Sclerosis Therapy with LUCID-MS Program, Completes Phase 1 Trials
Quantum BioPharma has completed Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and filed an IND with the FDA, addressing the critical unmet need for neuroprotective treatments.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary therapy for multiple sclerosis, LUCID-MS, designed to directly protect or restore myelin integrity—a key factor in the loss of mobility and bodily control experienced by MS patients. The company announced the completion of Phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
In April 2026, Quantum BioPharma reached a significant milestone by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS. This step moves the candidate closer to clinical development in patients, addressing a critical gap in MS treatment: the lack of therapies that directly target the underlying neurodegeneration and myelin damage driving long-term disease progression.
Multiple sclerosis remains one of the most challenging neurological diseases, affecting more than 2.8 million people worldwide and approximately 1 million in the USA. The disease is a chronic autoimmune and neurodegenerative condition in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can progressively worsen over time. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Quantum BioPharma’s LUCID-MS program is built around this unmet need. The patented therapeutic candidate targets demyelination and provides neuroprotection, with the goal of addressing loss of mobility and function. The positive Phase 1 safety data and IND submission represent important steps toward potentially offering patients a therapy that could modify the course of the disease, not just manage symptoms.
For investors, the latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
About BioMedWire: BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.